ICURe Funding
ICURe Funding opportunity
ICURe is a 16-week full-time program with up to £35,000 in funding available to help research teams get out of the lab and explore the commercial potential of their research and or their technology, the funding is broken down into two halves.
The first 3 months of funding will go towards salaries, plus £20,000 to explore the market and meet potential clients & investors and also validate the need for their technology.
In the next 3 months, if decide to go ahead with the start-up, the salary will be paid to create the company, maintain the market traction with potential clients, and then going forth applying for a £300,000 grant from Innovate to start your company
To be eligible you need to apply with a team of 4, have an entrepreneurial lead, a principle scientific advisor, a TTO member, and a business advisor.
The boot camp will take place w/c 6th November.
Applications are welcome from all UK universities and Research Council-funded institutes.
Applications close Tuesday 3rd October 3023
You can apply online by clicking the link: https://www.icureprogramme.com/courses/icure-explore-november-2023/
More
Harwell Campus Named UK’s Most Successful Science Campus
Harwell Science and Innovation Campus has been recognised as the UK’s most successful science campus by the UK Science Park Association (UKSPA). This accolade highlights Harwell’s growth and its significant contributions to the UK’s innovation economy, particularly in fields like life sciences, space exploration, energy technology, and quantum computing. A […]
Nu Quantum Launches Qubit-Photon Interface (QPI) for Scalable Quantum Computing
Nu Quantum Launches Qubit-Photon Interface (QPI) for Scalable Quantum Computing! Nu Quantum is thrilled to announce a game-changing development: the Qubit-Photon Interface (QPI). This innovative prototype is set to connect different quantum computers in a quantum network, making modular and distributed quantum computing a reality. As the demand for quantum […]
MitoRx Publishes Study on AP39’s Effectiveness in Reducing Obesity
MitoRx Therapeutics has published a study in Pharmacological Research demonstrating that its mitochondrial-targeted sulfide-donor compound, AP39, significantly reduces weight gain and fatty liver. This study is the first to explore the potential of mitochondrial sulfide donors in addressing obesity-related disorders. AP39 was found to reduce weight gain by 32%, lower […]